首页> 外文学位 >R & D of an Innovative Composite Scaffold Incorporated with Phytoestrogenic Icaritin for Treatment of Steroid-associated Osteonecrosis Lesion in Rabbits.
【24h】

R & D of an Innovative Composite Scaffold Incorporated with Phytoestrogenic Icaritin for Treatment of Steroid-associated Osteonecrosis Lesion in Rabbits.

机译:结合植物雌激素伊卡替丁的创新型复合支架的研发,用于治疗类固醇相关的骨坏死性病变。

获取原文
获取原文并翻译 | 示例

摘要

Bone defect is a common orthopaedic problem caused by many pathologic disorders such as tumor, trauma or metabolic diseases, including osteonecrosis (ON). ON is a disabling clinical condition characterized by the death of osteocytes, aggregation of marrow fat cells, a decrease in activity of bone marrow stem cells (BMSCs) pool, and degeneration of trabecular bone matrix, which affect more frequently young adults that usually leads to bone and articular cartilage destruction in joints, especially in hip and knee. High dose of steroid is one of the risk factors associated with ON, which sometimes is used for treatment of some medical conditions such as systemic lupus erythematosus (SLE), organ transplantation, asthma, rheumatologic arthritis (RA), and severe acute respiratory syndrome (SARS). Core decompression has been efficacious for treatment of early ON stages when the necrotic lesion is still small in size. However, ON lesion, weakens the cancellous bone within and adjacent to the necrotic region. Thus orthopaedic challenges in repair for steroid-associated ON lesion after core decompression may include the impaired osteogenic potential of stem-cell-pool under the influence of pulsed steroid and lack of platform for bone or/and neovascularization ingrowth after removal of large size necrotic bone.;The proposed strategies for treatment of steroid-associated ON lesion are to provide biocompatible scaffold with required structure to fill the defect area after core decompression and osteogenic stimulator facilitating the repair of ON lesion. Previous works show that the PLGA (poly-lactic glycolic acid) and TCP (tricalcium phosphate) have good biocompatibility, osteoconduction and biodegradation to be used in bone defect repair, however no significant osteopromotive effects. Many endogenous factors are osteopromotive and also eventually osteoinductive, such as bone morphogenic proteins (BMPs). As an extraneous molecular, Icaritin, a small molecule derived from Epimedium -derived flavonoids (EF), is found to be able to facilitate matrix calcification, stimulate osteogenesis and inhibit adipogenesis of BMSCs. The present thesis work hypothesizes that the PLGA/TCP incorporating Icaritin to form a porous composite scaffold is osteopromotive and is able to enhance the repair of necrotic bone defect with steroid-associated ON after core decompression.;The findings implied that the porous composite PLGA/TCP/Icaritin scaffold would be an appropriate osteopromotive scaffold implant or bone graft substitute biomaterial for potential application in skeletal tissue engineering. It was the first study to incorporate or homogenize the Chinese herbal molecule into the porous composite biomaterials for medical testing. Though the osteopromotive effect in ON model was observed in vivo, the molecular mechanism of osteogenesis remains for future investigations. (Abstract shortened by UMI.).
机译:骨缺损是由许多病理性疾病(例如肿瘤,创伤或代谢性疾病,包括骨坏死(ON))引起的常见骨科问题。 ON是一种致残性临床疾病,其特征是骨细胞死亡,骨髓脂肪细胞聚集,骨髓干细胞(BMSCs)池活性降低以及小梁骨基质变性,这些疾病通常会影响年轻人,通常导致关节,尤其是髋部和膝盖的骨和关节软骨破坏。高剂量的类固醇是与ON相关的危险因素之一,有时会用于治疗某些医学病症,例如系统性红斑狼疮(SLE),器官移植,哮喘,风湿性关节炎(RA)和严重的急性呼吸综合征( SARS)。当坏死性病变的大小仍然较小时,核心减压治疗有效。但是,ON病变会削弱坏死区域内和附近的松质骨。因此,在核心减压后修复与类固醇相关的ON病变的骨科挑战可能包括在脉冲类固醇的影响下干细胞池的成骨能力受损,以及在去除大尺寸坏死骨后缺乏骨平台和/或新血管形成向内生长建议的治疗类固醇相关性ON病变的策略是提供具有所需结构的生物相容性支架,以在核心减压后填充缺损区域,并采用成骨刺激剂促进ON病变的修复。先前的工作表明,PLGA(聚乳酸乙醇酸)和TCP(磷酸三钙)具有良好的生物相容性,骨传导性和生物降解性,可用于骨缺损修复,但没有明显的促骨作用。许多内源性因子促进骨质生长,最终也具有骨诱导性,例如骨形态发生蛋白(BMP)。作为一种外源分子,伊卡肽素是源自淫羊der类黄酮(EF)的小分子,能够促进基质钙化,刺激成骨作用并抑制BMSC的脂肪形成。本论文的工作假设是,结合叶绿素的PLGA / TCP形成骨质疏松复合支架,能够促进骨质减压后与类固醇结合的ON对坏死性骨缺损的修复。 TCP /伊利替林支架将是一种合适的骨促进支架植入物或骨移植替代生物材料,有望在骨骼组织工程中应用。这是第一项将中草药分子掺入或均质化到多孔复合生物材料中进行医学测试的研究。尽管在体内观察到了ON模型中的骨促进作用,但是成骨的分子机制仍然有待进一步研究。 (摘要由UMI缩短。)。

著录项

  • 作者

    Xie, Xinhui.;

  • 作者单位

    The Chinese University of Hong Kong (Hong Kong).;

  • 授予单位 The Chinese University of Hong Kong (Hong Kong).;
  • 学科 Health Sciences Medicine and Surgery.;Health Sciences Pharmacy.;Engineering Biomedical.;Engineering Materials Science.
  • 学位 Ph.D.
  • 年度 2010
  • 页码 193 p.
  • 总页数 193
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号